2018
article
OpenAlex
Marissa L. Ostroff, Kristin Aloi, William E. Bryan, Jason Moss et autres
OBJECTIVES: To describe hypoglycemic events in a Veterans Affairs (VA) community living center (CLC) population and to determine predictive risk factors associated with hypoglycemia. DESIGN: Retrospective, exploratory, observational chart review. SETTING: Tertiary-care VA Healthcare System CLC. PATIENTS: Residents residing in a VA …
us
(code pays fourni par la source)
Accès ouvert
2017
article
OpenAlex
David M. Lee, C. Thomas, Fuhua Xu, Richard R. Yeoman et autres
us
(code pays fourni par la source)
Accès ouvert
2016
article
OpenAlex
C. Thomas, M. Glogowska, Steve Keysar, Antonio Jimeno
us
(code pays fourni par la source)
2014
article
OpenAlex
Borislav A. Alexiev, C. Thomas, Ying Zou
us
(code pays fourni par la source)
Accès ouvert
2013
article
OpenAlex
D.M. Lee, C. Thomas, Fan Xu, Alison Y. Ting et autres
us
(code pays fourni par la source)
2013
article
OpenAlex
Matthias Wolff, Janine Bailey, Jason Moss, Richard Sloane et autres
Accès ouvert
2012
article
OpenAlex
D.M. Lee, Alison Y. Ting, C. Thomas, Cecily V. Bishop et autres
us
(code pays fourni par la source)
2010
article
OpenAlex
R. Gerritse, Ronald Peek, Fred C.G.J. Sweep, C. Thomas et autres
Transplantation of cryopreserved intact ovaries from cancer patients is a technically challenging option for restoring fertility after sterilizing cancer therapy. In this paper we describe an assay based on 17ß-oestradiol (oestradiol) production, to monitor the functional damage sustained by the ovarian tissue …
nl
(code pays fourni par la source)
Accès ouvert
2010
article
OpenAlex
D. Lee, Matthew Burns, C. Thomas, Richard R. Yeoman et autres
us
(code pays fourni par la source)
Accès ouvert
2010
article
OpenAlex
D.M. Lee, C. Thomas, Richard R. Yeoman, Don P. Wolf et autres
us
(code pays fourni par la source)
Accès ouvert
2008
article
OpenAlex
D.M. Lee, C. Thomas, Richard R. Yeoman, Mary B. Zelinski
us
(code pays fourni par la source)
2008
conference-abstract
OpenAlex
Dimitra Tsavachidou, Nizar M. Tannir, C. Thomas, Gorden Mills et autres
16016 Background: Renal carcinoma patients treated with anti-VEGF therapy (bevacizumab) typically exhibit 10–15% partial responses with detectable primary tumor shrinkage in 70% of the cases (Rini B.I., Clin Cancer Res, 2007). It is not well known which factors determine response or are …